Assembly Biosciences announced that the company will have an oral presentation of the full data set from the Phase 1b study of ABI-H0731 at the upcoming American Association for the Study of Liver Diseases, or AASLD. The oral presentation at AASLD will review final results of the Phase 1b study in patients with chronic hepatitis B, or HBV infection, including safety, tolerability and pharmacokinetics of ABI-H0731, as well as quantitative changes in HBV DNA, RNA and viral antigens. ABI-H0731 was safe and well tolerated, with dose dependent antiviral effects at doses ranging from 100 to 400 mg given orally once daily, and RNA declines paralleled the observed DNA declines. The company presented interim results of the study at the Annual Meeting of the European Association for the Study of the Liver, or EASL.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.